Table 3A.

Seroresponse rates as defined by the percentage of subjects with ≥ 4-fold increase as compared to baseline values of anti-PT IgG, anti-FHA IgG, anti-PRN IgG and anti-PT neutralizing antibody titers at 7 and 28 d after vaccination.

	Day 7				Day 28
	BNA's aP	BNA's TdaP	Adacel®		BNA's aP	BNA's TdaP	Adacel®
	N = 19	18	19		19	18	19
	n (%) (95% CI)	n (%) (95% CI)	n (%) (95% CI)	P-value	n (%) (95% CI)	n (%) (95% CI)	n (%) (95% CI)	P-value
Anti-PT ELISA	9 (47.37) (25.0–70.0)	8 (44.44) (21.0–67.0)	11 (57.89) (36.0–80.0)	0.688 [1]	17 (89.47) (76.0–100.0)	17 (94.44) (84.0–100.0)	16 (84.21) (68.0–100.0)	0.862 [2]
Anti- FHA ELISA	16 (84.21) (68.0–100.0)	14 (77.78) (59.0–97.0)	6 (31.58) (11.0–52.0)	0.001* [1]	19 (100.00) (100.0–100.0)	17 (94.44) (84.0–100.0)	16 (84.21) (68.0–100.0)	0.209 [2]
Anti-PRN ELISA	9 (47.37) (25.0–70.0)	8 (44.44) (21.0–67.0)	11 (57.89) (36.0–80.0)	0.688 [1]	15 (78.95) (61.0–97.0)	15 (83.33) (66.0–100.0)	16 (84.21) (68.0–100.0)	1.000 [2]
Anti-PT Nab	10 (52.63) (30.0–75.0)	12 (66.67) (45.0–88.0)	16 (84.21) (68.0–100.0)	0.110 [1]	17 (89.47) (76.0–100.0)	16 (88.89) (74.0–100.0)	16 (84.21) (68.0–100.0)	1.000 [1]

[1] Based on chi-square test, [2] Based on Fisher's exact,

^*P < 0.05, statistically significant.